Loading clinical trials...
Loading clinical trials...
A Phase 1a/1b, Blinded, Placebo-Controlled Study of the Safety, Tolerability and Pharmacokinetics of Single- and Multiple Ascending Doses of ABI-1179 in Healthy Subjects and in Subjects Who Are Seropositive for Herpes Simplex Virus Type 2 With Recurrent Genital Herpes
Conditions
Interventions
ABI-1179
ABI-1179 Placebo
Locations
18
United States
Alliance for Multispecialty Research
Kansas City, Missouri, United States
Rochester Clinical Research
Rochester, New York, United States
Seattle Clinical Research Center
Seattle, Washington, United States
University of Washington Virology Research Clinic
Seattle, Washington, United States
East Sydney Doctors
Darlinghurst, Australia, Australia
Royal Melbourne Hospital
Parkville, Australia, Australia
Start Date
December 8, 2024
Primary Completion Date
January 19, 2026
Completion Date
January 19, 2026
Last Updated
March 23, 2026
Lead Sponsor
Assembly Biosciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions